-dopa
Dopamine-like drugs used in Parkinson's disease or to lower prolactin.
- Drugs ending in -dopa: 14
- Approved somewhere: 5
- With a US drug page: 5
- Stem
- -dopa
- Class
- Dopamine-like drugs used in Parkinson's disease or to lower prolactin
- Sub-stems
- -opamine
- Most common targets
- DRD3 (2), DDC (2), ADRB1 (2), Adrenergic receptor (1), Adrenergic receptor alpha-2 (1)
Approved and clinical-stage drugs in ChEMBL whose names ending in -dopa or one of its sub-stems, matched by spelling; those with a US drug page link to it.
| Acts on | |||
|---|---|---|---|
| Droxidopa | Approved | Adrenergic receptor | Adrenergic receptor agonist |
| Levodopa | Approved | DRD3 | Dopamine D3 receptor agonist |
| Methyldopa | Approved | Adrenergic receptor alpha-2 | Adrenergic receptor alpha-2 agonist |
| Methyldopa (racemic) | Phase 1 | — | — |
| Carbidopa anhydrous | Approved | DDC | DOPA decarboxylase inhibitor |
| Fluorodopa | Phase 3 | — | Diagnostic agent |
| Foslevodopa | Phase 3 | ADRB1 | Beta-1 adrenergic receptor agonist |
| Melevodopa | Phase 2 | — | — |
| Foscarbidopa | Phase 1 | DDC | DOPA decarboxylase inhibitor |
| Etilevodopa | — | DRD3 | Dopamine D3 receptor agonist |
| Dopamine | Approved | ADRB1 | Beta-1 adrenergic receptor agonist |
| Ibopamine | Phase 2 | — | — |
| Octopamine | Phase 2 | — | — |
| Tolpropamine | Phase 2 | — | — |
Stem from WHO, The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances (2024); description written by Arca. Drugs, stages, targets and mechanisms from ChEMBL (CC BY-SA 3.0). WHO